CD180

Across TCGA pan-cancer cohorts, CD180 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD180 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD180 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD180 expression acts as an unfavorable survival marker.

CCRCC, GBM, and COAD are the cancer types where CD180 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	38	view →
GBM	DFS	Median	All	0.265	0.486	<.001	18	view →
COAD	DFS	Tertile	II,III,IV	0.896	1.000	.040	12	view →
PDAC	DFS	Tertile	All	0.228	0.367	.017	12	view →
LUAD	OS	Median	II,III,IV	0.863	0.999	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD180–CCRCC (DFS)

Open the CCRCC breakdown →